Statistical Thinking for Non-Statisticians in Drug Regulation - Hardcover

Statistical Thinking for Non-Statisticians in Drug Regulation - Hardcover

$153.22
Sale price  $153.22 Regular price 
Skip to product information
Statistical Thinking for Non-Statisticians in Drug Regulation - Hardcover

Statistical Thinking for Non-Statisticians in Drug Regulation - Hardcover

$153.22
Sale price  $153.22 Regular price 

by Richard Kay (Author)

STATISTICAL THINKING FOR NON-STATISTICIANS IN DRUG REGULATION

Statistical methods in the pharmaceutical industry are accepted as a key element in the design and analysis of clinical studies. Increasingly, the medical and scientific community are aligning with the regulatory authorities and recognizing that correct statistical methodology is essential as the basis for valid conclusions. In order for those correct and robust methods to be successfully employed there needs to be effective communication across disciplines at all stages of the planning, conducting, analyzing and reporting of clinical studies associated with the development and evaluation of new drugs and devices.

Statistical Thinking for Non-Statisticians in Drug Regulation provides a comprehensive in-depth guide to statistical methodology for pharmaceutical industry professionals, including physicians, investigators, medical science liaisons, clinical research scientists, medical writers, regulatory personnel, statistical programmers, senior data managers and those working in pharmacovigilance. The author's years of experience and up-to-date familiarity with pharmaceutical regulations and statistical practice within the wider clinical community make this an essential guide for the those working in and with the industry.

The third edition of Statistical Thinking for Non-Statisticians in Drug Regulation includes:

  • A detailed new chapter on Estimands in line with the 2019 Addendum to ICH E9
  • Major new sections on topics including Combining Hierarchical Testing and Alpha Adjustment, Biosimilars, Restricted Mean Survival Time, Composite Endpoints and Cumulative Incidence Functions, Adjusting for Cross-Over in Oncology, Inverse Propensity Score Weighting, and Network Meta-Analysis
  • Updated coverage of many existing topics to reflect new and revised guidance from regulatory authorities and author experience

Statistical Thinking for Non-Statisticians in Drug Regulation is a valuable guide for pharmaceutical and medical device industry professionals, as well as statisticians joining the pharmaceutical industry and students and teachers of drug development.

Back Jacket

Statistical methods in the pharmaceutical industry are accepted as a key element in the design and analysis of clinical studies. Increasingly, the medical and scientific community are aligning with the regulatory authorities and recognizing that correct statistical methodology is essential as the basis for valid conclusions. In order for those correct and robust methods to be successfully employed there needs to be effective communication across disciplines at all stages of the planning, conducting, analyzing and reporting of clinical studies associated with the development and evaluation of new drugs and devices.

Statistical Thinking for Non-Statisticians in Drug Regulation provides a comprehensive in-depth guide to statistical methodology for pharmaceutical industry professionals, including physicians, investigators, medical science liaisons, clinical research scientists, medical writers, regulatory personnel, statistical programmers, senior data managers and those working in pharmacovigilance. The author's years of experience and up-to-date familiarity with pharmaceutical regulations and statistical practice within the wider clinical community make this an essential guide for the those working in and with the industry.

The third edition of Statistical Thinking for Non-Statisticians in Drug Regulation includes:

  • A detailed new chapter on Estimands in line with the 2019 Addendum to ICH E9
  • Major new sections on topics including Combining Hierarchical Testing and Alpha Adjustment, Biosimilars, Restricted Mean Survival Time, Composite Endpoints and Cumulative Incidence Functions, Adjusting for Cross-Over in Oncology, Inverse Propensity Score Weighting, and Network Meta-Analysis
  • Updated coverage of many existing topics to reflect new and revised guidance from regulatory authorities and author experience

Statistical Thinking for Non-Statisticians in Drug Regulation is a valuable guide for pharmaceutical and medical device industry professionals, as well as statisticians joining the pharmaceutical industry and students and teachers of drug development.

Author Biography

Richard Kay, PhD is a Visiting Professor at the School of Pharmacy and Pharmaceutical Medicine, Cardiff University, UK, and a longtime statistical consultant for the pharmaceutical industry. He provides consultancy and training services for pharmaceutical companies and research institutions.

Number of Pages: 432
Dimensions: 0.94 x 9.61 x 6.69 IN
Publication Date: February 28, 2023

Intentional design

We make things that work better and last longer. Our products solve real problems with clean design.

Quality first

We obsess over the details and strive to deliver the best products at the best prices, every time.

Customer care

We're always on your side: keeping our loyal customers happy is our top priority and number one goal.

Feature 1

Made with care and unconditionally loved by our customers, this signature bestseller exceeds all expectations.

Feature 2

Made with care and unconditionally loved by our customers, this signature bestseller exceeds all expectations.

At the heart of every product lies a unique story, driven by our passion for quality and innovation. Each item enhances your everyday life and sparks joy.